Systemic Lupus Erythematosus

  • Stephen Mark Olmstead
  • Joe Venzor
  • David P. Huston

Abstract

Systemic lupus erythematosis is an autoimmune disease of unknown etiology (1–3). Clinical features include fatigue, fever, dermatitis, photosensitivity, alopecia, arthritis, serositis, hematologic abnormalities, mucosal ulcerations, Raynaud’s phenomenon, neurological disease, and glomerulonephritis. Serologic features include false-positive VDRL, circulating immune complexes, depressed complement levels, and antibodies to nuclear constituents, leukocytes, and erythrocytes. The diagnosis should be made if a patient fulfills four or more of the criteria established by the American College of Rheumatology (4). Although genetic (5), hormonal (6), and environmental (7) factors have been implicated in the etiology and modification of disease activity, immunologic abnormalities are postulated as essential in the pathogenesis of disease (8–14).

Keywords

Systemic Lupus Erythematosus Lupus Nephritis Lupus Patient Congenital Heart Block Lupus Nephritis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Osier W: On the visceral manifestations of the erythema group of skin diseases. Am J Med Sci 127: 1, 1904.CrossRefGoogle Scholar
  2. 2.
    Dubois EL, ed: Lupus Erythematosus: A Review of the Current Status of Discoid and Systemic Lupus Erythematosus and Their Variants, 2nd revised ed. University of Southern California Press, Los Angeles, 1976.Google Scholar
  3. 3.
    Fries JF: The clinical aspects of systemic lupus erythematosus. Med Clin North Am 61: 229, 1977.Google Scholar
  4. 4.
    Tan EM, Cohen AS, Fries JF, et al.: Special article: the 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Winchester RJ, Nunez-Roldan A: Some genetic aspects of systemic lupus erythematosus. Arthritis Rheum 25: 833, 1982.PubMedCrossRefGoogle Scholar
  6. 6.
    Lahita RG, Bradlow L, Fishman J, et al.: Estrogen metabolism in systemic lupus erythematosus: patients and family members. Arthritis Rheum 25: 843, 1982.PubMedCrossRefGoogle Scholar
  7. 7.
    Pincus T: Studies regarding a possible function for viruses in the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 25: 847, 1982.PubMedCrossRefGoogle Scholar
  8. 8.
    Messner RP, Lindstrom FD, Williams RC Jr: Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus. J Clin Invest 52: 3046, 1973.PubMedCrossRefGoogle Scholar
  9. 9.
    Fauci, AS, Steinberg AD, Haynes BF, et al.: Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol 121: 1473, 1978.PubMedGoogle Scholar
  10. 10.
    Paty JG Jr, Sienknecht CW, Townes AS, et al.: Impaired cell-mediated immunity in systemic lupus erythematosus (SLE): a controlled study of 23 untreated patients. Am J Med 59: 769, 1975.PubMedCrossRefGoogle Scholar
  11. 11.
    Abdou NI, Sagawa A, Pascual E, et al.: Suppressor T cell abnormality in idiopathic systemic lupus erythematosus. Clin Immunol Immunopathol 6: 192, 1976.PubMedCrossRefGoogle Scholar
  12. 12.
    Smolen JS, Chused TM, Leiserson WM, et al.: Heterogeneity of immunoregulatory T cell subsets in systemic lupus erythematosus: correlation with clinical features. Am J Med 72: 783, 1982.PubMedCrossRefGoogle Scholar
  13. 13.
    Winfield JB, Shaw M, Yamada A, et al.: Subset specificity of antilymphocyte antibodies in systemic lupus erythematosus. II. Preferential reactivity with T4+ cells is associated with relative depletion of autologous T4+ cells. Arthritis Rheum 30: 162, 1987.PubMedCrossRefGoogle Scholar
  14. 14.
    Morimoto C, Steinberg AD, Letvin N, et al.: A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. J Clin Invest 79: 762, 1987.PubMedCrossRefGoogle Scholar
  15. 15.
    Frank MM, Austen KF, Claman HN: Samter’s Immunologic Diseases, vol. 2, chapter 37. Little, Brown, Boston, pp 671673, 1995.Google Scholar
  16. 16.
    Theofilopoulos AN: The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 16: 90–98, 1995.PubMedCrossRefGoogle Scholar
  17. 17.
    Wofsy D, Ledbetter JA, Hendler PL, et al.: Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol 134: 852, 1985.PubMedGoogle Scholar
  18. 18.
    Mountz JD, Wu J, Cheng J, et al.: Autoimmune disease. A problem of defective apoptosis. Aythritis Rheuma 37: 1415 1420, 1994.Google Scholar
  19. 19.
    Cheng J, Zhou T, Liu C, et al.: Protection from Fas-mediated apoptosis by a souluble form of the Fas molecule. Science, 263: 1759–1762, 1994.PubMedCrossRefGoogle Scholar
  20. 20.
    Koffler D, Carr RI, Agnello V, et al.: Antibodies to poly-nucleotides in human sera, antigenic specificity and relation to disease. J Exp Med 134: 294, 1971.PubMedCrossRefGoogle Scholar
  21. 21.
    Notman DD, Kurata N, Tan EM: Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med 83: 464, 1975.PubMedCrossRefGoogle Scholar
  22. 22.
    Blaese M, Grayson J, Steinberg AD: Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus. Am J Med 69: 345, 1980.PubMedCrossRefGoogle Scholar
  23. 23.
    Zubler RH, Huang Y, Miescher PA: Mechanisms of physiologic B cell responses and B cell hyperactivity in systemic lupus erythematosus. Springer Semin Immunopathol 9: 195, 1986.PubMedCrossRefGoogle Scholar
  24. 24.
    Koffler D, Agnello V, Thoburn R, et al.: Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med 134 (S): 169, 1971.PubMedGoogle Scholar
  25. 25.
    Bretjens J, Ossi E, Albini B, et al.: Disseminated immune deposits in lupus erythematosus. Arthritis Rheum 20: 962, 1977.CrossRefGoogle Scholar
  26. 26.
    Suzuki Y, Oite T, Shimizu F, et al.: Solubilization of immune complex deposits by native 7S IgG molecules in lupus glomerulonephritis—a possible antigen excess effect on rheumatoid factor—IgG complexes. Clin Exp Immunol 58: 663, 1984.PubMedGoogle Scholar
  27. 27.
    Malide D, Londono I, Russo P, Bendayan M: Ultrastructural localization of DNA in immune deposits of human lupus nephritis. Am J Pathol 143: 304, 1993.PubMedGoogle Scholar
  28. 28.
    Harbeck RJ, Bardana EJ, Kohler PF, et al.: DNA: anti-DNA complexes: their detection in systemic lupus erythematosus sera. J Clin Invest 52: 789, 1973.PubMedCrossRefGoogle Scholar
  29. 29.
    Sano H, Morimoto C: Isolation of DNA from DNA/AntiDNA immune complexes in systemic lupus erythematosus. J Immunol 126: 538, 1981.PubMedGoogle Scholar
  30. 30.
    Morimoto C, Sano H, Abe T, et al.: Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/Anti-DNA antibody immune complexes. J Immunol 139: 1960, 1982.Google Scholar
  31. 31.
    Datta SK, Patel H, Berry D: Induction of a cationic shift in IgG anti-DNA autoantibodies, role of T helper cells with the classical and novel phenotypes in three murine models of lupus nephritis. J Exp Med 165: 1252, 1987.PubMedCrossRefGoogle Scholar
  32. 32.
    Chetrit EB, Dunsky EH, Wollner S, et al.: In vivo clearance and tissue uptake of an anti-DNA monoclonal antibody and its complexes with DNA. Clin Exp Immunol 60: 159, 1985.PubMedGoogle Scholar
  33. 33.
    Couser WG: Mechanisms of glomerular injury in immune-complex disease. Kidney Int 28: 569, 1985.PubMedCrossRefGoogle Scholar
  34. 34.
    Wener MH, Mannik M: Mechanisms of immune deposit formation in renal glomeruli. Springer Semin Immunopathol 9: 219, 1986.PubMedCrossRefGoogle Scholar
  35. 35.
    Gay S, Losman MJ, Koopman WJ, et al.: Interaction of DNA with connective tissue matrix proteins reveals preferential binding to type V collagen. J Immunol 135: 1097, 1985.PubMedGoogle Scholar
  36. 36.
    Isenberg DA, Collins C: Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients. J Clin Invest 76: 287, 1985.PubMedCrossRefGoogle Scholar
  37. 37.
    Madaio MP, Carlson J, Cataldo J, et al.: Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol 138: 9883, 1987Google Scholar
  38. 38.
    Rudnicki RD, Gresham GE, Rothfield NF: The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 2: 323, 1975.PubMedGoogle Scholar
  39. 39.
    Urman JD, Rothfield NF: Corticosteroid treatment of systemic lupus erythematosus. JAMA 238: 2272, 1977.PubMedCrossRefGoogle Scholar
  40. 40.
    Carey RA, Harvey AM, Howard JE: The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of disseminated lupus erythematosus and periarteritis nodosa. Bull Johns Hopkins Hosp 87: 425, 1950.PubMedGoogle Scholar
  41. 41.
    Klemperer P, Pollack AD, Baehr G: Pathology of disseminated lupus erythematosus. Arch Pathol 32: 569, 1941.Google Scholar
  42. 42.
    Pickering G, Bywaters EGL, Danielli JF, et al.: Treatment of systemic lupus erythematosus with steroids. Report to the Medical Research Council by the Collagen Diseases and Hypersensitivity Panel. Br Med J 2: 915, 1961.CrossRefGoogle Scholar
  43. 43.
    Feinglass EJ, Arnett FC, Dorsch CA, et al.: Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 55: 323, 1976.PubMedCrossRefGoogle Scholar
  44. 44.
    Kaplan D: Treatment of systemic lupus erythematosus. Arthritis Rheum 20 (S): 175, 1977.Google Scholar
  45. 45.
    Merrell M, Shulman LE: Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chron Dis 1: 12, 1955.PubMedCrossRefGoogle Scholar
  46. 46.
    Kellum RE, Haserick JR: Systemic lupus erythematosus: a statistical evaluation of mortality based on a consecutive series of 299 patients. Arch Intern Med 113: 200, 1964.PubMedCrossRefGoogle Scholar
  47. 47.
    Dubois EL, Wierzchowiecki MD, Cox MB, et al.: Duration and death in systemic lupus erythematosus: an analysis of 249 cases. JAMA 227: 1399, 1974.PubMedCrossRefGoogle Scholar
  48. 48.
    Leonhardt T: Long-term prognosis of systemic lupus erythematosus. Acta Med Scand 445: 440, 1966.Google Scholar
  49. 49.
    Estes D, Christain CL: The natural history of systemic lupus erythematosus by prospective analysis. Medicine 50: 85, 1971.PubMedCrossRefGoogle Scholar
  50. 50.
    Cameron JS, Turner DR, Ogg CS, et al.: Systemic lupus with nephritis: a long-term study. Q J Med 48: 1, 1979.PubMedGoogle Scholar
  51. 51.
    Swaak AJG, Nossent JC, Bronsveld W, Van Rooyen A, Nieuwenhuys EJ, Theuns L, Smeenk RJT: Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48: 447, 1989.PubMedCrossRefGoogle Scholar
  52. 52.
    Wallace DJ, Podell T, Weiner J, et al.: Systemic lupus erythematosus-survival patterns: experience with 609 patients. JAMA 245: 934, 1981.PubMedCrossRefGoogle Scholar
  53. 53.
    Pollak V, Pirani CL, Schwartz F: The natural history of renal manifestations of systemic lupus erythematosus. J Lab Clin Med 53: 493, 1964.Google Scholar
  54. 54.
    Karsh J, Klippel JH, Balow JE, et al.: Mortality in lupus nephritis. Arthritis Rheum 22: 764, 1979.PubMedCrossRefGoogle Scholar
  55. 55.
    Cohen AS, Reynolds WE, Franklin EC, et al.: Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 21: 643, 1971.Google Scholar
  56. 56.
    Davis P, Atkins BC, Josse RG, et al.: Criteria for classification of SLE. Br Med J 3: 88, 1973.PubMedCrossRefGoogle Scholar
  57. 57.
    Sinniah R, Feng PH: Lupus nephritis: correlation between light electron microscopic and immunofluorescent findings and renal function. Clin Nephrol 6: 340, 1976.PubMedGoogle Scholar
  58. 58.
    Wallace DJ, Podell TE, Weiner JM: Lupus nephritis: experience with 230 patients in a private practice from 1950 to 1980. Am J Med 72: 209, 1982.PubMedCrossRefGoogle Scholar
  59. 59.
    Dubis EL, Tuffanelli DL: Clinical manifestations of systemic lupus erythematosus: complete analysis of 520 cases. JAMA 190: 104, 1964.CrossRefGoogle Scholar
  60. 60.
    Rothfield NF, McClusky RT, Baldwin DS: Renal disease in systemic lupus erythematosus. N Engl J Med 269: 537, 1963.PubMedCrossRefGoogle Scholar
  61. 61.
    Meislin AG, Rothfield N: Systemic lupus erythematosus in childhood. Pediatrics 42: 37, 1968.PubMedGoogle Scholar
  62. 62.
    Dillard MG, Tillman RL, Sampson CC: Lupus nephritis: correlation between the clinical course and presence of electron-dense deposits. Lab Invest 32: 261, 1975.PubMedGoogle Scholar
  63. 63.
    Koffler D, Agnello V, Carr I, et al.: Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus. Am J Pathol 56: 305, 1969.PubMedGoogle Scholar
  64. 64.
    Dujovne I, Pollak VE, Pirani CL, et al.: The distribution and character of glomerular deposits in systemic lupus erythematosus. Kidney Int 2: 33, 1972.PubMedCrossRefGoogle Scholar
  65. 65.
    Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J: Kidney biopsy in SLE. I. A clinical-morphologic evaluation.Google Scholar
  66. 66.
    Churg J: Renal disease: Classification and Atlas of Glomerular Diseases. Igaku-Shoin, New York, p 359, 1982.Google Scholar
  67. 67.
    Haakenstad AO, Mannik M: Saturation of the reticuloendothelial system with soluble immune complexes. J Immunol 112: 1939, 1974.PubMedGoogle Scholar
  68. 68.
    Gershwin ME, Steinberg AD: Qualitative characteristics of anti-DNA antibodies in lupus nephritis. Arthritis Rheum 17: 947, 1974.PubMedCrossRefGoogle Scholar
  69. 69.
    Southeimer RD, Gilliam JN: DNA antibody class, subclass, and complement fixation in systemic lupus erythematosus with and without nephritis. Clin Immunol Immunopathol 10: 459, 1978.CrossRefGoogle Scholar
  70. 70.
    Winfield JB, Faiferman I, Koffler D: Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. J Clin Invest 59: 90, 1977PubMedCrossRefGoogle Scholar
  71. 71.
    Phillips R, Lomnitzer R, Wadee AA, et al.: Defective monocyte function in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 34: 69, 1985.PubMedCrossRefGoogle Scholar
  72. 72.
    Shirakawa F, Yamashita U, Suzulci H: Decrease in HLADR positive monocytes in patients with systemic lupus erythematosus (SLE). J Immunol 134: 3560, 1985.PubMedGoogle Scholar
  73. 73.
    Sano H, Morimoto C: DNA isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content. J Immunol 128: 1341, 1982.PubMedGoogle Scholar
  74. 74.
    Pirani CL, Olesnicky L: Role of electron microscopy in the classification of lupus nephritis. Am J Kidney Dis 2 (51): 150, 1982.PubMedGoogle Scholar
  75. 75.
    Comerford FR, Cohen AS: The nephropathy of systemic lupus erythematosus. An assessment of clinical, light, and electron microscopic criteria. Medicine 46: 425, 1967.CrossRefGoogle Scholar
  76. 76.
    Baldwin DS, Gluck MC, Lowenstein J, et al.: Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med 62: 12, 1977.PubMedCrossRefGoogle Scholar
  77. 77.
    Grishman E, Porush JG, Lee SL, et al.: Renal biopsies in lupus nephritis. Nephron 10: 25, 1973.PubMedCrossRefGoogle Scholar
  78. 78.
    Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J: Kidney biopsy in SLE. I. A clinical-morphologic evaluation.Google Scholar
  79. 79.
    Brenner BM, Rector FC Jr: The Kidney. W.B. Saunders, Philadelphia, p 1286, 1991.Google Scholar
  80. 80.
    McLaughlin J, Gladman DD, Urowitz MB, Bombardier C, Farewell VT, Cole E: Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. Arthritis Rheum 34: 1268, 1991.PubMedCrossRefGoogle Scholar
  81. 81.
    Zimmerman SW, Jenkins PG, Shelp WP, et al.: Progression from minimal or focal to diffuse proliferative lupus nephritis. Lab Invest 32: 665, 1975.PubMedGoogle Scholar
  82. 82.
    Baldwin DG, Gallo GR: Lupus nephritis. Clin Rheum Dis 1: 639, 1975.Google Scholar
  83. 83.
    Mery JP, Morel-Maroger L, Boelaert J, et al.: Evolution anatomoclinique des glomerulites diffuses et focales au course du lupus erythemateux dissemine. J Urol Nephrol 45: 321, 1973.Google Scholar
  84. 84.
    Ginzler EM, Nicastri AD, Chun-Kuo C, et al.: Progression of mesangial and focal to diffuse lupus nephritis. N Engl J Med 291: 693, 1974.PubMedCrossRefGoogle Scholar
  85. 85.
    Decker JL, Steinberg AD, Reinertsen JL, et al.: Systemic lupus erythematosus: evolving concepts. Ann Intern Med 91: 587, 1979.PubMedCrossRefGoogle Scholar
  86. 86.
    Baldwin DS, Lowenstein J, Rothfield NF, et al.: The clinical course of proliferative and membranous forms of lupus nephritis. Ann Intern Med 73: 929, 1970.PubMedCrossRefGoogle Scholar
  87. 87.
    Stamenkovic I, Farre H, Donath A, et al.: Renal biopsy in SLE irrespective of clinical finding: long term follow-up. Clin Nephrol 26: 109, 1986.PubMedGoogle Scholar
  88. 88.
    Farquhar MG, Palade GE: Functional evidence for the existence of a third cell type in the renal glomerulus. J Cell Biol 13: 55, 1962.PubMedCrossRefGoogle Scholar
  89. 89.
    Tsumagari T, Fukumoto S, Kinjo M, et al.: Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Human Pathol 16: 43, 1985.CrossRefGoogle Scholar
  90. 90.
    Balow JE: Therapeutic trials in lupus nephritis-problems related to renal histology, monitoring of therapy, and measures of outcome. Nephron 27: 171, 1981.PubMedCrossRefGoogle Scholar
  91. 91.
    Pollak VE, Pirani CL: Pathology of the kidney in systemic lupus erythematosus: Serial renal biopsy studies and the effects of therapy on kidney lesions. In: EL Dubois, ed, Lupus Erythematosus, 2nd ed. University of Southern California Press, Los Angeles, 1974.Google Scholar
  92. 92.
    Austin HA, Muenz LR, Joyce KM, et al.: Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25: 689, 1984.PubMedCrossRefGoogle Scholar
  93. 93.
    Austin HA, Muenz LR, Joyce KM, et al.: Prognostic factors in lupus nephritis, contribution of renal histologic data. Am J Med 75: 382, 1983.PubMedCrossRefGoogle Scholar
  94. 94.
    Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M: The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 72: 779, 1989.PubMedGoogle Scholar
  95. 95.
    Esdaile JM, Federgreen W, Quintal H, Suissa S, Hayslett JP, Kashgarian M: Predictors of one year outcome in lupus nephritis: the importance of renal biopsy. Q J Med 81: 907, 1991.PubMedGoogle Scholar
  96. 96.
    Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ: Role of pathology indices in the management of severe lupus glomerulonephritis. Kidney Int 42: 743, 1992.PubMedCrossRefGoogle Scholar
  97. 97.
    Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ: Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Am J Kidney Dis 21: 374, 1993.PubMedGoogle Scholar
  98. 98.
    Wernick RM, Smith DL, Houghton DC, Phillips DS, Booth JL, Runckel DN, Johnson DS, Brown KK, Gaboury CL: Reliability of histologic scoring for lupus nephritis: a community-based evaluation. Ann Intern Med 119: 805, 1993.PubMedCrossRefGoogle Scholar
  99. 99.
    Schwartz MM, Bernstein J, Hill GS, Holley K, Phillips EA, Lupus Nephritis Collaborative Study Group: Kidney Int 36: 891, 1989.PubMedCrossRefGoogle Scholar
  100. 100.
    Iseki K, Miyasato F, Oura T, Uehara H, Nishime K, Fukiyama K: An epidemiologic analysis of end-stage lupus nephritis. Am J Kidney Dis 23: 547, 1994.PubMedGoogle Scholar
  101. 101.
    Symchych PS, Perrin EV: Thrombosis of main pulmonary artery in nephrosis. Thromboembolism as a complication of nephrosis. Am J Dis Child 110: 636, 1965.PubMedGoogle Scholar
  102. 102.
    Appel GB, Williams GS, Meltzer JI, et al.: Renal vein thrombosis, nephrotic syndrome, and systemic lupus erythematosus. Ann Intern Med 85: 310, 1976.PubMedCrossRefGoogle Scholar
  103. 103.
    Cade R, Spooner G, Juncos L, et al.: Chronic renal vein thrombosis. Am J Med 63: 387, 1977.PubMedCrossRefGoogle Scholar
  104. 104.
    Kant KS, Pollak VE, Weiss MA, et al.: Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine 60: 71, 1981.PubMedCrossRefGoogle Scholar
  105. 105.
    Schleissner LA, Sheehan WW, Orselli RC.: Lupus erythematosus in a patient with amyloidosis, adrenal insufficiency, and subsequent immunoblastic sarcoma. Arthritis Rheum 19: 249, 1976.PubMedCrossRefGoogle Scholar
  106. 106.
    Ring RW, Falls WF: Renal amyloidosis development in a case of systemic lupus erythematosus. Clin Nephrol 6: 467, 1976.Google Scholar
  107. 107.
    Webb S, Segura F, Cervantes F, et al.: Systemic lupus erythematosus and amyloidosis. Arthritis Rheum 22: 554, 1979.PubMedCrossRefGoogle Scholar
  108. 108.
    Huston DP, McAdam PWJ, Balow JE: Amyloidosis in systemic lupus erythematosus. Am J Med 70: 320, 1981.PubMedCrossRefGoogle Scholar
  109. 109.
    Budman DR, Steinberg AD: Hypertension and renal disease in systemic lupus erythematosus. Arch Intern Med 136: 1003, 1976.PubMedCrossRefGoogle Scholar
  110. 110.
    Seleznick MJ, Fries JF: Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 21: 73, 1991.PubMedCrossRefGoogle Scholar
  111. 111.
    Urowitz MB, Bookman AM, Koehler BE, et al.: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221, 1976.PubMedCrossRefGoogle Scholar
  112. 112.
    Bulkley BH, Roberts WC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 58: 243, 1975.PubMedCrossRefGoogle Scholar
  113. 113.
    Petri M, Spence D, Bone LR, Hochberg MC: Coronary artery disease risk factors in the Johns Hopkins lupus cohort: prevalence, recognition by patients, and preventive practices. Medicine 71: 291, 1992.PubMedCrossRefGoogle Scholar
  114. 114.
    Leong KH, Koh ET, Feng PH, Boey ML: Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21: 1264, 1994.PubMedGoogle Scholar
  115. 115.
    Garcia DL, Rennke HG, Brenner BM, Anderson S: Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation. J Clin Invest 80: 867–874, 1987.PubMedCrossRefGoogle Scholar
  116. 116.
    El-Shaboury AH, Hayes TM: Hyperlipidemia in asthmatic patients receiving long-term steroid therapy. Br Med J 2: 85, 1973.PubMedCrossRefGoogle Scholar
  117. 117.
    Hardin NJ, Minick R, Murphy GE: Experimental induction of atherosclerosis by the synergy of allergic injury to arteries and lipid rich diet. Am J Pathol 73: 301, 1973.PubMedGoogle Scholar
  118. 118.
    Minick CR, Stemerman MB, Insull W: Role of endothelium and hypercholesterolemia in intimai thickening and lipid accumulation. Am J Pathol 95: 131, 1979.PubMedGoogle Scholar
  119. 119.
    Glueck HI, Kant KS, Weiss MA, et al.: Thrombosis in systemic lupus erythematosus: relation to the presence of circulating anticoagulants. Arch Intern Med 145: 1389, 1985.PubMedCrossRefGoogle Scholar
  120. 120.
    Petri M, Rheinschmidt M, Whiting-O’Keefe Q, et al.: The frequency of lupus anticoagulant in systemic lupus erythematosus. Ann Intern Med 106: 524, 1987PubMedCrossRefGoogle Scholar
  121. 121.
    Coritsidis G, Rifici V, Gupta S, et al.: Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 39: 858–866, 1991.PubMedCrossRefGoogle Scholar
  122. 122.
    Klippel JH, Karsh J, Stahl NI, et al.: A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum 22: 1321, 1979.PubMedCrossRefGoogle Scholar
  123. 123.
    Friedman EA, Rutherford JW: Pregnancy and lupus erythematosus. Obstet Gynecol 8: 601, 1956.PubMedGoogle Scholar
  124. 124.
    Garsenstein M, Pollak VE, Kark RM: Systemic lupus erythematosus and pregnancy. N Engl J Med 267: 165, 1962.PubMedCrossRefGoogle Scholar
  125. 125.
    Houser MT, Fish AJ, Tagatz GE, et al.: Pregnancy and systemic lupus erythematosus. Am J Obstet Gynecol 138: 409, 1980.PubMedGoogle Scholar
  126. 126.
    Tozman ECS, Urowitz MB, Gladman DD: Systemic lupus erythematosus and pregnancy. J Rheumatol 7: 624, 1980.PubMedGoogle Scholar
  127. 127.
    Zulman JI, Talai N, Hoffman GS, Epstein WV: Problems associated with the management of pregnancies in patients with systemic lupus erythematosus. J Rheumatol 7: 37, 1980.PubMedGoogle Scholar
  128. 128.
    Hayslett JP, Lynn RI: Effect of pregnancy in patients with lupus nephropathy. Kidney Int 18: 207, 1980.PubMedCrossRefGoogle Scholar
  129. 129.
    Petri M. Lupus and pregnancy. Bull Rheumat Dis 44: 1, 1995.PubMedGoogle Scholar
  130. 130.
    Packham DK, Lam SS, Nichols K, et al.: Lupus nephritis and pregnancy. Q J Med 83: 315, 1992.PubMedGoogle Scholar
  131. 131.
    Derksen RH, Bruinse HW, de Groot PG, Kater L: Pregnancy in systemic lupus erythematosus: a prospective study. Lupus 3: 149, 1994.PubMedCrossRefGoogle Scholar
  132. 132.
    Lockshin MD, Druzin ML, Goli S, et al.: Antibody to cardiolipin as a predictor of fetal distress or death in pregnancy patients with systemic lupus erythematosus. N Engl J Med 313: 152, 1985.PubMedCrossRefGoogle Scholar
  133. 133.
    Branch DW, Scott JR, Kochenour NK, et al.: Obstetric complications associated with the lupus anticoagulant. N Engl J Med 313: 1322, 1985.PubMedCrossRefGoogle Scholar
  134. 134.
    Nossent JC, Swaak AJG: Systemic lupus erythematosus: IV. Analaysis of the interrelationship with pregnancy. J Rheumatol 17: 798–802, 1989.Google Scholar
  135. 135.
    McCarty-Farid GA: Antiphospholipid antibodies in systemic lupus erythematosus. Curr Opinion Rheumatol 6: 493, 1994.CrossRefGoogle Scholar
  136. 136.
    Petri M: Systemic lupus erythematosus and pregnancy. Rheumat Dis Clin North Am 20: 87, 1994.Google Scholar
  137. 137.
    Buyon JP, Winchester RJ, Slade SG, Arnett F, Copel J, Friedman D, Lockshin MD: Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 36: 1263, 1993.PubMedCrossRefGoogle Scholar
  138. 138.
    Lee AL, Frank MB, McCubbin VR, et al.: Autoantibodies of neonatal lupus erythematosus. J Invest Dermatol 102: 963966, 1994.Google Scholar
  139. 139.
    Buyon JP: Neonatal lupus syndromes. Curr Opinion Rheumatol 6: 523–529, 1994.CrossRefGoogle Scholar
  140. 140.
    Kalush F, Rimon E, Keller A, et al.: Neonatal lupus erythematosus with cardiac involvement in offspring of mothers with experimenatal systemic lupus erythematosus. J Clin Immunol 14: 314–322, 1994.PubMedCrossRefGoogle Scholar
  141. 141.
    Burnet FM, Holmes MC: The natural history of the NZB/ NZW Pl hybrid mouse: a laboratory model of systemic lupus. Aust Ann Med 14: 185, 1965.PubMedGoogle Scholar
  142. 142.
    Lambert PH, Dixon FJ: Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med 127: 507, 1968.PubMedCrossRefGoogle Scholar
  143. 143.
    Huston DP, Steinberg AD: Animal models of human systemic lupus erythematosus. Yale J Biol Med 52: 289, 1979.PubMedGoogle Scholar
  144. 144.
    Helyer BJ, Howie JB: Renal disease associated with positive lupus erythematosus tests in cross-bred strains of mice. Nature 197: 197, 1963.PubMedCrossRefGoogle Scholar
  145. 145.
    Raveche ES, Novotny EA, Hansen, CT et al.: Genetic studies in NZB mice: V. Recombinant inbred lines demonstrate that separate genes control autoimmune phenotype. J Exp Med 153: 1187, 1981.PubMedCrossRefGoogle Scholar
  146. 146.
    Steinberg AD, Raveche ES, Laskin CA, et al.: Systemic lupus erythematosus: insights from animal models. Ann Intern Med 100: 714, 1984.PubMedCrossRefGoogle Scholar
  147. 147.
    Rotzin BL, Palmer E: The contribution of NZW genes to lupus-like disease in (NZBxNZW)F1 mice. J Exp Med 165: 1237, 1987.CrossRefGoogle Scholar
  148. 148.
    Klassen LW, Budman DR, Williams GW, et al.: Ribavirin: efficacy in the treatment of murine autoimmune disease. Science 195: 787, 1977.PubMedCrossRefGoogle Scholar
  149. 149.
    Roubinian JR, Papoian R, Talal N: Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest 59: 1066, 1977.PubMedCrossRefGoogle Scholar
  150. 150.
    Duvic M, Steinberg AD, Klassen LW: Effect of anti-estrogen, Nafoxidine, on NZB/W autoimmune disease. Arthritis Rheum 21: 414, 1978.PubMedCrossRefGoogle Scholar
  151. 151.
    Melez KA, Reeves JP, Steinberg AD: Regulation of the expression of autoimmunity in NZBxNZW Fl mice by sex hormones. J Immunopharm 1: 27, 1978.CrossRefGoogle Scholar
  152. 152.
    Lucas JA, Ahmed SA, Casey ML, et al.: Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White Fl mice fed dehydroisoandrosterone. J Clin Invest 75: 2091, 1985.PubMedCrossRefGoogle Scholar
  153. 153.
    Lahita RG, Bradlow HL, Ginter E, et al.: Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 30: 241, 1987.PubMedCrossRefGoogle Scholar
  154. 154.
    Jungers P, Kuttenn F, Liote F, et al.: Hormonal modulation of systemic lupus erythematosus: preliminary clinical and hormonal results with cyproterone acetate. Arthritis Rheum 28: 1243–50, 1985.PubMedCrossRefGoogle Scholar
  155. 155.
    Asherson RA, Lahita RG: Sex hormone modulation in systemic lupus erythematosus: still a therapeutic option? Ann Rheum Dis 50: 897–898, 1991.PubMedCrossRefGoogle Scholar
  156. 156.
    Krakauer RS, Strober W, Rippeon DL, et al.: Prevention of autoimmune disease in experimental systemic lupus erythematosus by the administration of soluble immune response suppressor. Science 196: 56, 1977.PubMedCrossRefGoogle Scholar
  157. 157.
    Reinertsen JL, Steinberg AD: In vivo immune response suppression by the supernatant from concanavalin A-activated spleen cells. J Immunol 19: 217, 1977.Google Scholar
  158. 158.
    Zurier RB, Sayadoff DM, Torrey SB, et al.: Prostaglandin E, treatment of NZB/W mice. Prevention of glomerulonephritis. Arthritis Rheum 20: 1449, 1977.PubMedCrossRefGoogle Scholar
  159. 159.
    Zurier RB: Prostaglandins, immune responses, and murine lupus. Arthritis Rheum 25: 804, 1982.PubMedCrossRefGoogle Scholar
  160. 160.
    Denman. AM, Denman EJ, Holborow EJ: Effects of anti-lymphocyte globulin on kidney disease in (NZBxNZW)F1 mice. Lancet 2: 841, 1966.Google Scholar
  161. 161.
    Denman AM, Russell AS, Loewi G, et al.: Immunopathology of New Zealand Black mice treated with antilymphocyte globulin. Immunology 20: 973, 1971.PubMedGoogle Scholar
  162. 162.
    Kotzin BL, Strober S: Reversal of NZB/NZW disease with total lymphoid irradiation. J Exp Med 150: 371, 1979.PubMedCrossRefGoogle Scholar
  163. 163.
    Steinberg AD, Talal N: Suppression of antibodies to nucleic acids with polyinosinic polycytidylic acid and cyclophosphamide in murine lupus. Clin Exp Immunol 7: 687, 1971.Google Scholar
  164. 164.
    Borel H, Bastian D, Cooper B, et al.: A possible new therapy of systemic lupus erythematosus (SLE). Ann NY Acad Sci 475: 296, 1986.PubMedCrossRefGoogle Scholar
  165. 165.
    Hurd ER, Johnston JM, Okita JR, et al.: Prevention of glomerulonephritis and prolonged survival in New Zealand Black/New Zealand White Fl hybrid mice fed an essential fatty acid deficient diet. J Clin Invest 67: 476, 1981.PubMedCrossRefGoogle Scholar
  166. 166.
    Prickett JD, Robinson DR, Steinberg AD: Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB/ NZW Fl mice. J Clin Invest 68: 556, 1981.PubMedCrossRefGoogle Scholar
  167. 167.
    Robinson DR, Prickett DR, Makoul GT, et al.: Dietary fish oil reduces progression of established renal disease in (NZBxNZW)F1 mice and delays renal disease in BXSB and MRL/1 strains. Arthritis Rheum 29: 539, 1986.PubMedCrossRefGoogle Scholar
  168. 168.
    Fischer S, Weber PC: Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 307: 165, 1984.PubMedCrossRefGoogle Scholar
  169. 169.
    Hall AV, Parbtani A, Clark WF, et al.: Abrogation of MRL/ 1pr Lupus nephritis by dietary flaxseed. Am J Kidney Dis 22: 326–332, 1993.PubMedGoogle Scholar
  170. 170.
    Casey TP: Systemic lupus erythematosus in NZBxNZW hybrid mice treated with the corticosteroid drug betamethasone. J Lab Clin Med 71: 390, 1968.PubMedGoogle Scholar
  171. 171.
    Gelfand MC, Steinberg AD: Therapeutic studies in NZB/W mice. II. Relative efficacy of azathioprine, cyclophosphamide, and methylprednisone. Arthritis Rheum 15: 247, 1972.PubMedCrossRefGoogle Scholar
  172. 172.
    Hahn BH, Bagby MK, Hamilton TR, et al.: Comparison of therapeutic and immunosuppressive effects of azathioprine, prednisolone and combined therapy in NZB/NZW mice. Arthritis Rheum 16: 163, 1973.PubMedCrossRefGoogle Scholar
  173. 173.
    Steinberg AD, Gelfand MC, Hardin JA, et al.: Therapeutic studies in NZB/W mice. II. Relationship between renal status and efficacy of immunosuppressive drug therapy. Arthritis Rheum 18: 9, 1975.PubMedCrossRefGoogle Scholar
  174. 174.
    Casey TP: Immunosuppression by cyclophosphamide in NZBxNZW mice with lupus nephritis. Blood 32: 436, 1968.PubMedGoogle Scholar
  175. 175.
    Horowitz RE, Dubois EL, Weiner J, et al.: Cyclophosphamide treatment of mouse systemic lupus erythematosus. Lab Invest 21: 199, 1969.PubMedGoogle Scholar
  176. 176.
    Russell PJ, Hicks JD, Burnet FM: Cyclophosphamide treatment of kidney disease in (NZBxNZW)F1 mice. Lancet 1: 1279, 1966.CrossRefGoogle Scholar
  177. 177.
    Russell PJ, Hicks JD: Cyclophosphamide treatment of renal disease in (NZBxNZW)F1 hybrid mice. Lancet 1: 440, 1968.PubMedCrossRefGoogle Scholar
  178. 178.
    Gunn HC: Successful treatment of autoimmunity in (NZBxNZW)F1 mice with cyclosporin and (Nva2)cyclosporine: I. Reduction of autoantibodies. Clin Exp Immunol 64: 225, 1986.PubMedGoogle Scholar
  179. 179.
    Gunn HC, Ryffel B: Successful treatment of autoimmunity in (NZBxNZW)F1 mice with cyclosporine and (Nva2) cyclosporine Il: Reduction of glomerulonephritis. Clin Exp Immunol 64: 234, 1986.PubMedGoogle Scholar
  180. 180.
    Entani C, Izumino K, Iida H, et al.: Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-1pr/lpr mice. Nephron 64: 471–475, 1993.PubMedCrossRefGoogle Scholar
  181. 181.
    Ito S, Ueno M, Arakawa M, et al.: Theraputic effect of 15- deoxyspergualin on the progression of lupus nephritis in MRL mice. Immunopathological analyses. Clin Exp Immunol 81: 446–453, 1990.PubMedCrossRefGoogle Scholar
  182. 182.
    Okubo M, Inoune K, Ameniya K: High-dose 15deoxyspergualin monotherapy surpasses methylprednisolone in its theraputic effect on advanced lupus nephritis in New Zealand Black/White Fl hybrid mice, and low-dose combination may be synergisitic. Neph Dial Transplant 8: 720–724, 1993.Google Scholar
  183. 183.
    Andrzejenski C Jr, Stollar BD, Lalor TM, et al.: Hybridoma autoantibodies to DNA. J Immunol 124: 1499, 1980.Google Scholar
  184. 184.
    Hahn BH, Ebling F, Freeman S, et al.: Production of monoclonal murine antibodies to DNA by somatic cell hybrids. Arthritis Rheum 23: 942, 1980.PubMedCrossRefGoogle Scholar
  185. 185.
    Rauch J, Lafer E, Andrzejewski C, et al.: Monoclonal lupus autoantibodies. Arthritis Rheum 25: 744, 1982.PubMedCrossRefGoogle Scholar
  186. 186.
    Hahn B: Characteristics of pathogenic subpopulations of antibodies to DNA. Arthritis Rheum 25: 747, 1982.PubMedCrossRefGoogle Scholar
  187. 187.
    Wofsy D, Seaman WE: Reversal of advanced murine lupus in NZB/NZW Fl mice by treatment with monoclonal antibody to L3T4. J Immunol 138:3247, 1S87.Google Scholar
  188. 188.
    Coleman DL, Ruef C: Interleukin-6: an autocrine regulator of mesangial cell growth. Kidney Int 38: 249, 1990.PubMedCrossRefGoogle Scholar
  189. 189.
    Iwano M, Dohi K, Hirata E, et al.: Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 40: 16, 1993.PubMedGoogle Scholar
  190. 190.
    Kiberd BA: Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 4: 58, 1993.PubMedGoogle Scholar
  191. 191.
    Albert DA, Hadler NM, Ropes MW: Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus. Arthritis Rheum 22: 945, 1979.PubMedCrossRefGoogle Scholar
  192. 192.
    Pollak VE, Pirani CL, Kark RM: Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 57: 495, 1961.PubMedGoogle Scholar
  193. 193.
    Bell PRF, Calman KC, Wood RFM, et al.: Reversal of acute clinical and experimental organ rejection using large doses of intravenous methylprednisolone. Lancet 1: 876, 1971.PubMedCrossRefGoogle Scholar
  194. 194.
    Mussche MM, Ringoir SMG, Lameire NN: High intravenous doses of methylprednisolone for acute cadaveric renal allograft rejection. Nephron 16: 287, 1976.PubMedCrossRefGoogle Scholar
  195. 195.
    Cathcart ES, Scheinberg MA, Idelson BA, et al.: Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet 1: 163, 1976.PubMedCrossRefGoogle Scholar
  196. 196.
    Nebout T, Sobel A, Lagrue G: Intravenous methylprednisolone pulses in diffuse proliferative lupus nephritis (letter). Lancet 1: 909, 1977.PubMedCrossRefGoogle Scholar
  197. 197.
    Ponticelli C, Zucchelli P, Banfi G, et al.: Treatment of diffuse proliferative lupus nephritis by intravenous high-dose methylprednisolone. Q J Med 201: 16, 1982.Google Scholar
  198. 198.
    Dosa S, Mallick NP, Lawler W, et al.: The treatment of lupus nephritis by methylprednisolone pulse therapy. Postgrad Med J 54: 628, 1978.PubMedCrossRefGoogle Scholar
  199. 199.
    Harisdangkul V, Rockhold L, Myers A: Lupus nephritis: efficacy of monthly pulse therapy with intravenous methylprednisolone. South Med J 82: 321, 1989.PubMedCrossRefGoogle Scholar
  200. 200.
    Kimberly RP, Lockshin MD, Sherman RL, et al.: High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 70: 817, 1981.PubMedCrossRefGoogle Scholar
  201. 201.
    Ballou SP, Khan MA, Kushner I: Intravenous pulse methylprednisolone followed by alternate day corticosteroid therapy in lupus erythematosus: a prospective evaluation. J Rheumatol 12: 944, 1985.PubMedGoogle Scholar
  202. 202.
    Carette S, Kuppel JH, Decker JL, et al.: Controlled studies of oral immunosuppressive drugs in lupus nephritis. A longterm follow-up. Ann Intern Med 99: 1, 1983.PubMedCrossRefGoogle Scholar
  203. 203.
    Sztejnbok M, Stewart A, Diamond H, et al.: Azathioprine in the treatment of systemic lupus erythematosus: a controlled study. Arthritis Rheum 14: 639, 1971.PubMedCrossRefGoogle Scholar
  204. 204.
    Donadio JV Jr, Holley KE, Wagoner RD, et al.: Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 77: 829, 1972.PubMedCrossRefGoogle Scholar
  205. 205.
    Cade R, Spooner G, Schlein E, et al.: Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 10: 37, 1973.PubMedCrossRefGoogle Scholar
  206. 206.
    Donadio JV Jr, Holley KE, Wagoner RD, et al.: Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum 17: 573, 1974.PubMedCrossRefGoogle Scholar
  207. 207.
    Hahn BH, Kantor OS, Osterland CK: Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med 83: 597, 1975.PubMedCrossRefGoogle Scholar
  208. 208.
    Donadio JV Jr, Holley KE, Ferguson RH, et al.: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299: 1151, 1978.PubMedCrossRefGoogle Scholar
  209. 209.
    Austin HA, Kuppel JH, Balow JE, et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614, 1986.PubMedCrossRefGoogle Scholar
  210. 210.
    Felson DT, Anderson J: Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone al.one in lupus nephritis. N Engl J Med 311: 1528, 1984.PubMedCrossRefGoogle Scholar
  211. 211.
    Dinant HJ, Decker JL, Klippel JH, et al.: Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 96: 728, 1982.PubMedCrossRefGoogle Scholar
  212. 212.
    Ginzler E, Diamond H, Guttadauria M, et al.: Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum 19: 693, 1976.PubMedCrossRefGoogle Scholar
  213. 213.
    McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318: 1423, 1988.PubMedCrossRefGoogle Scholar
  214. 214.
    Boumpas DT, Austin HA, Vaughn EM, Lippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741, 1992.PubMedCrossRefGoogle Scholar
  215. 215.
    McInnes PM, Schuttinga J, Sanslone WR, et al.: The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide. Arthritis Rheum 37: 1000–1006, 1994.PubMedCrossRefGoogle Scholar
  216. 216.
    Jones JV, Cumming RH, Bucknall RC, Asplin CM: Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1: 709, 1976.PubMedCrossRefGoogle Scholar
  217. 217.
    Jones JV, Cumming RH, Bacon PA, et al.: Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 48: 555, 1979.PubMedGoogle Scholar
  218. 218.
    Moran CJ, Parry HF: Plasmapheresis in systemic lupus erythematosus. Br Med J 1: 1573, 1977.PubMedCrossRefGoogle Scholar
  219. 219.
    Schlansky R, DeHoratius RJ, Pincus T, Tung KSK: Plasmapheresis in systemic lupus erythematosus. Arthritis Rheum 24: 49, 1981.PubMedCrossRefGoogle Scholar
  220. 220.
    Lockwood CM, Pussell B, Wilson CB, Peters DK: Plasma exchange in nephritis. Adv Nephrol 8: 383, 1979.Google Scholar
  221. 221.
    Lockwood CM, Peters DK: Plasma exchange in glomerulonephritis and related vasculitides. Ann Rev Med 31: 687, 1979.Google Scholar
  222. 222.
    Schildermans F, Dequeker J, DePutte IV: Plasmapheresis combined with corticosteroids and cyclophosphamide in uncontrolled active systemic lupus erythematosus. J Rheumatol 6: 687, 1979.PubMedGoogle Scholar
  223. 223.
    Lockwood CM, Rees AJ, Pussell B, et al.: Experience of the use of plasma exchange in the management of potentially fulminating glomerulonephritis and SLE. Exp Hematol 5: 117s, 1977.Google Scholar
  224. 224.
    Hubbard HC, Portnoy B: Systemic lupus erythematosus in pregnancy treated with plasmapheresis. Br J Dermatol 101: 87, 1979.PubMedCrossRefGoogle Scholar
  225. 225.
    Isbister JP, Ralston M, Wright ••: Fulminant lupus pneumonitis with acute renal failure and RBC aplasia. Arch Intern Med 141: 1081, 1981.PubMedCrossRefGoogle Scholar
  226. 226.
    Fitchen JJ, Cline MJ, Saxon A, et al.: Serum inhibitors of hemopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: recovery after plasma exchange. Am J Med 66: 537, 1979.PubMedCrossRefGoogle Scholar
  227. 227.
    McKenzie PE, Taylor AE, Woodroffe AJ, et al.: Plasmapheresis in glomerulonephritis. Clin Nephrol 12: 97, 1979.PubMedGoogle Scholar
  228. 228.
    Rossen RD, Hersh EM, Sharp JT, et al.: Effect of plasma exchange on circulating immune complexes and antibody formation in patients with cyclophosphamide and prednisone. Am J Med 63: 674, 1977.PubMedCrossRefGoogle Scholar
  229. 229.
    Young DW, Thompson RA, McKenzie PH: Plasmapheresis in hereditary angioneurotic edema and systemic lupus erythematosus. Arch Intern Med 140: 127, 1980.PubMedCrossRefGoogle Scholar
  230. 230.
    Blacklock HA, Hill RS, Bridle M, et al.: Therapeutic plasmapheresis by continuous flow centrifugation. N Z Med J 92: 145, 1980.PubMedGoogle Scholar
  231. 231.
    Parry JF, Moran CJ, Smith ML, et al.: Plasma exchange in systemic lupus erythematosus. Ann Rheum Dis 40: 224, 1981.PubMedCrossRefGoogle Scholar
  232. 232.
    Jones JV, Robinson MF, Parciany RK, et al.: Therapeutic plasmapheresis in systemic lupus erythematosus: effect on immune complexes and antibodies to DNA. Arthritis Rheum 24: 1113, 1981.PubMedCrossRefGoogle Scholar
  233. 233.
    Abdou NI, Lindsley HB, Pollock A, et al.: Plasmapheresis in active SLE: effects on clinical serum, and cellular abnormalities. Case report. Clin Immunol Immunopathol 19:44, 1981.Google Scholar
  234. 234.
    Lockwood CM, Worlledge S, Nichols A, et al.: Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 300: 524, 1979.PubMedCrossRefGoogle Scholar
  235. 235.
    Habersetzer R, Samtleben W, Blumenstein M, et al.: Plasma exchange in systemic lupus erythematosus. Int J Artif Organs 6: 39, 1983.PubMedGoogle Scholar
  236. 236.
    Vangelista A, Frasca G, Orsi C, et al.: Short-term plasmapheresis in acute lupus nephritis. Int J Artif Organs 6: 43, 1983.PubMedGoogle Scholar
  237. 237.
    Hamblin Ti, Smith DS: Long-term exchange (a feasible treatment in systemic lupus erythematosus and other diseases). La Ricerca Clin Lab 13: 95, 1983.Google Scholar
  238. 238.
    Moriconi L, Ferri C, Fanara G, et al.: Plasma exchange in the treatment of lupus nephritis. Int J Artif Organs 6: 35, 1983.PubMedGoogle Scholar
  239. 239.
    Schena FP, Manno C, Carabellese S, et al.: Plasma exchange in systemic lupus erythematosus. Int J Artif Organs 6: 29, 1983.PubMedGoogle Scholar
  240. 240.
    Schroeder JO, Haus HE, Loffler H: Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 107: 334, 1987.CrossRefGoogle Scholar
  241. 241.
    Clark WF, Lindsay RM, Cattran DC, et al.: Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study. Can Med Assoc J 125: 171, 1981.PubMedGoogle Scholar
  242. 242.
    Clark WF, Cattran DC, Balfe JW, et al.: Chronic plasma exchange in systemic lupus erythematosus nephritis. Proc Eur Dial Transplant Assoc 20: 629, 1983.PubMedGoogle Scholar
  243. 243.
    Terman DS, Buffaloe G, Mattioli C, et al.: Extracorporal immunoabsorption: initial experience in human systemic lupus erythematosus. Lancet 2: 824, 1979.PubMedCrossRefGoogle Scholar
  244. 244.
    Suzuki K, Hara M, Haragai M, et al.: Continuous removal of anti-DNA antibody, using an extracorporeal immunoabsorption system, in patients with systemic lupus erythematosus. Arthritis Rheum 34: 1546–52, 1991.PubMedCrossRefGoogle Scholar
  245. 245.
    Wei N, Klippel JH, Huston DP, et al.: Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1: 17, 1983.PubMedCrossRefGoogle Scholar
  246. 246.
    Huston DP, Wei N, Klima E, Hall RP, et al.: Immunochemical effects of plasmapheresis in systemic lupus erythematosus (SLE). Arthritis Rheum 24: 92 (5), 1981.Google Scholar
  247. 247.
    Tsokos GC, Balow JE, Huston DP, et al.: Effect of plasmapheresis on T and B lymphocyte functions in patients with systemic lupus erythematosus: a double blind study. Clin Exp Immunol 48: 449, 1982.PubMedGoogle Scholar
  248. 248.
    Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326: 1373, 1992.PubMedCrossRefGoogle Scholar
  249. 249.
    Euler HE, Schroeder JO, Harten P, et al.: Treatment-free remission in severe systemic lupus erythematosus following sychronization of plasmapheresis with subsequant pulse cyclophosphamide. Arthritis Rheum 12: 1784–1792, 1994.CrossRefGoogle Scholar
  250. 250.
    Euler HH, Guillevin L: Plasm apheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Med Interne (Paris) 145: 296–302, 1994.Google Scholar
  251. 251.
    Clark WF, Dau PC, Euler HH, et al.: Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide al.one in severe lupus: Design of the LPSG trial. J Clin Apheresis 6: 40–47, 1991.PubMedCrossRefGoogle Scholar
  252. 252.
    Huston DP, White MJ, Mattioli C, et al.: A controlled trial of plasmapheresis and cyclophosphamide therapy of lupus nephritis. Arthritis Rheum 26 (S): 33, 1983.Google Scholar
  253. 253.
    Strober S, Field E, Hoppe RT, et al.: Treatment of intractable lupus nephritis with total lymphoid irradiation. Ann Intern Med 102: 450, 1985.PubMedCrossRefGoogle Scholar
  254. 254.
    Ben-Chetrit E, Gross DJ, Braverman A, et al.: Total lymphoid irradiation in refractory systemic lupus erythematosus. Ann Intern Med 105: 58, 1986.PubMedCrossRefGoogle Scholar
  255. 255.
    Strober S, Farinas MC, Field EH, Solovera JJ, Kiberd BA, Myers BD, Hoppe RT: Treatment of lupus nephritis with total lymphoid irradiation. Observations during a 12–79-month followup. Arthritis Rheum 31: 850, 1988.PubMedCrossRefGoogle Scholar
  256. 256.
    The Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309: 809, 1983.CrossRefGoogle Scholar
  257. 257.
    Merion RM, David MD, White DJ, et al.: Cyclosporine: five years experience in cadaveric renal transplantation. N Engl J Med 310: 148, 1984.PubMedCrossRefGoogle Scholar
  258. 258.
    Borel JF, Ryffel B: Mechanism of action of ciclosporin: a continuing puzzle. In: R Schindler, ed, Ciclosporin in Autoimmune Diseases. First International Symposium. Springer-Verlag, Basel p 24, 1985.Google Scholar
  259. 259.
    Isenberg DA, Snaith ML, Morrow WJ, et al.: Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol 3: 63, 1981.CrossRefGoogle Scholar
  260. 260.
    Miescher PA, Miescher A: Combined ciclosporin-steroid treatment of systemic lupus erythematosus. In: R Schindler, ed, Ciclosporin in Autoimmune Diseases. First International Symposium. Springer-Verlag, Basel, p 337, 1985.Google Scholar
  261. 261.
    Miescher PA: Treatment of systemic lupus erythematosus. Springer Semin Immunopathol 9: 271, 1986.PubMedCrossRefGoogle Scholar
  262. 262.
    Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ: Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 9: 57, 1989.PubMedCrossRefGoogle Scholar
  263. 263.
    Mills JA: Medical Progress: Systemic lupus erythematosus. N Engl J Med 330: 1871, 1994.PubMedCrossRefGoogle Scholar
  264. 264.
    Radhakrishnan J, Kunis CL, Agati VD, Appel GB: Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42: 147, 1994.PubMedGoogle Scholar
  265. 265.
    Hariharan S, Pollak VE, Kant KS, Weiss MA, Wadhwa NK: Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod. Clin Nephrol 34: 61, 1990.PubMedGoogle Scholar
  266. 266.
    Pierucci A, Simonetti BM, Pecci G, et al.: Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med 320: 421, 1989.PubMedCrossRefGoogle Scholar
  267. 267.
    Espinoza LR, Jara LJ, Martinez-Osuna P, Silveira LH, Cuellar ML, Seleznick M: Refractory nephrotic syndrome in lupus nephritis favorable response to indomethacin therapy. Lupus 2: 9, 1993.PubMedCrossRefGoogle Scholar
  268. 268.
    Lin C-Y, Hsu H-C, Chiang H: Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 53: 303, 1989.PubMedCrossRefGoogle Scholar
  269. 269.
    Wacholtz MC, Lipsky PE: Treatment of lupus nephritis with CD5 PLUS, an immunocongugate of an anti-CD5 monoclonal antibody and ricin A chain. Arthritis Rheum 35: 837838, 1992.Google Scholar
  270. 270.
    Stafford FJ, Fleisher TA, Lee G, et al.: A pilot study of antiCD5 ricin A chain immmunocongugate in systemic lupus erythematosus. J Rhuematol 21: 2068–2070, 1994.Google Scholar
  271. 271.
    Eiser AR, Katz SM, Swartz C: Clinically occult diffuse proliferative lupus nephritis. Arch Intern Med 139: 1022, 1979.PubMedCrossRefGoogle Scholar
  272. 272.
    Ginzler EM, Diamond HS, Weiner M, et al.: A multicenter study of outcome in systemic lupus erythematosus. I. Entry variable as predictors of prognosis. Arthritis Rheum 25: 601, 1982.PubMedCrossRefGoogle Scholar
  273. 273.
    Coggins CH: Overview of treatment of lupus nephropathy. Am J Kidney Dis 2: 197, 1982.PubMedGoogle Scholar
  274. 274.
    Reidenberg MM: The chemical induction of systemic lupus erythematosus and lupus-like illnesses. Arthritis Rheum 24: 1004, 1981.PubMedCrossRefGoogle Scholar
  275. 275.
    Simon LS, Mills JA: Nonsteroidal anti-inflammatory drugs. N Engl J Med 302: 1179, 1980.PubMedCrossRefGoogle Scholar
  276. 276.
    Zipser RD, Henrich WL: Implications of nonsteroidal anti-inflammatory drug therapy. Am J Med 80 (SIA): 78, 1986.PubMedCrossRefGoogle Scholar
  277. 277.
    Karsh J, Kimberly RP, Stahl NI, et al.: Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus. Arthritis Rheum 23: 1401, 1980.PubMedCrossRefGoogle Scholar
  278. 278.
    Zemlickis D, Lishner M, Erlich R, Koren G: Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratogenesis Carcinog Mutagen 13: 139, 1993.PubMedCrossRefGoogle Scholar
  279. 279.
    Jungers P, Dougados M, Pellissier C, et al.: Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25: 618, 1982.PubMedCrossRefGoogle Scholar
  280. 280.
    Cheigh JS, Stenzel KH: End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 21: 2, 1993.PubMedGoogle Scholar
  281. 281.
    Nossent HC, Swaak TJG, Berden JHM: Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Am J Med 89: 169, 1990.PubMedCrossRefGoogle Scholar
  282. 282.
    Goss JA, Cole BR, Jendrisak MD, McCullough CS, So SKS, Windus DW, Hanto DW: Renal transplantation for systemic lupus erythematosus and recurrent lupus nephritis. A single-center experience and a review of the literature. Transplantation 52: 805, 1991.PubMedCrossRefGoogle Scholar
  283. 283.
    Mahajan SK, Ordoney NG, Spargo BH, et al.: Changing histopathology patterns in lupus nephropathy. Clin Nephrol 10: 1, 1978.PubMedGoogle Scholar
  284. 284.
    Gladman DD: Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 6: 487, 1994.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Stephen Mark Olmstead
    • 1
  • Joe Venzor
    • 2
  • David P. Huston
    • 2
  1. 1.GarlandUSA
  2. 2.Immunology Section, Department of MedicineBaylor College of MedicineHoustonUSA

Personalised recommendations